# EGR2

## Overview
EGR2, or early growth response 2, is a gene that encodes a zinc-finger transcription factor crucial for the regulation of myelination in the peripheral nervous system. The EGR2 protein is characterized by its three zinc-finger domains, which belong to the Cys2 His2 subfamily, enabling it to bind specific DNA sequences and regulate gene expression. This transcription factor is pivotal in the differentiation of Schwann cells and the formation of myelin sheaths, which are essential for efficient nerve signal transmission. Beyond its role in the nervous system, EGR2 is also involved in immune system regulation, particularly in T cell anergy and tolerance. Mutations in the EGR2 gene are linked to various peripheral neuropathies, including Charcot-Marie-Tooth disease and Dejerine-Sottas syndrome, underscoring its clinical significance in maintaining proper nerve function (Grosz2019A; Nafez2015Early; LeBlanc2007NeuropathyAssociated).

## Structure
The EGR2 protein is a zinc-finger transcription factor crucial for myelination in the peripheral nervous system. It contains three zinc-finger domains, which are part of the Cys2 His2 subfamily, characterized by cysteine and histidine residues that coordinate a zinc ion. These domains facilitate DNA binding, with each finger interacting with DNA in a modular, antiparallel fashion (Benos2002Probabilistic). The third zinc-finger domain is particularly significant, as mutations in this region, such as the p.Asp411Gly variant, can lead to severe neuropathies by reducing the protein's transcriptional regulatory activity (Grosz2019A).

The zinc-finger domains are essential for the protein's function, as they allow EGR2 to bind specific DNA sequences and regulate genes involved in myelin formation, such as PMP22 (Grosz2019A). The protein's structure is highly conserved, with the Asp411 residue being evolutionarily conserved, indicating its importance in maintaining the protein's function (Grosz2019A). While specific details on the primary, secondary, tertiary, or quaternary structures of EGR2 are not provided, the zinc-finger domains are a prominent feature of its molecular structure.

## Function
EGR2, also known as early growth response 2, is a transcription factor that plays a significant role in various cellular processes, particularly within the nervous and immune systems. In the nervous system, EGR2 is crucial for the regulation of peripheral nerve myelination, a process essential for proper nerve function. It is involved in the differentiation of Schwann cells, which are responsible for the formation of myelin sheaths around nerve fibers, thereby facilitating efficient nerve signal transmission (Nafez2015Early).

In the immune system, EGR2 is expressed in regulatory T cells (Tregs) and is associated with the induction of anergy in CD4 T cells. It inhibits the secretion of pro-inflammatory cytokines such as interferon-γ (IFN-γ) and IL-2, and enhances the expression of the E3 ligase Cbl-b, which is important for T cell tolerance and anergy (Okamura2012Roles). EGR2 also binds directly to the promoter of the cell cycle inhibitor p21cip1 in T cells, playing a role in controlling T cell proliferation (Okamura2012Roles).

EGR2 is active in both the cytoplasm and nucleus, with its zinc fingers containing nuclear localization signals, indicating its role in gene regulation within the nucleus (Nafez2015Early).

## Clinical Significance
Mutations in the EGR2 gene are associated with a range of peripheral neuropathies, including Charcot-Marie-Tooth disease (CMT) types 1D and 4E, Dejerine-Sottas syndrome (DSS), and congenital hypomyelinating neuropathy (CHN). These conditions vary in severity, with CMT1D often presenting milder symptoms in adulthood, while DSS and CHN are more severe and can have early onset (Grosz2019A; Warner1999Functional). 

Specific mutations, such as the S382R/D383Y double point mutation, are linked to severe forms of these neuropathies, including CHN, and can lead to significant myelin loss and slowed nerve conduction velocities (ArthurFarraj2006A). The p.Asp411Gly variant is another example, associated with severe early-onset DSS, affecting the zinc-finger domain crucial for DNA binding and transcriptional regulation (Grosz2019A).

EGR2 mutations can also result in axonal CMT, as seen with the p.R409Q mutation, which reduces the transcriptional activity of EGR2 and is linked to late-onset axonal CMT with variable severity (Sevilla2015The). Additionally, a homozygous deletion affecting an EGR2 enhancer has been associated with congenital amyelinating neuropathy, highlighting the gene's critical role in myelination (Funalot2012Homozygous).

## Interactions
EGR2 (early growth response 2) is a transcription factor that plays a crucial role in the regulation of myelin protein zero (Mpz) gene expression through its interaction with the SOX10 protein. EGR2 and SOX10 cooperatively bind to the Mpz intron element, a process essential for the activation of myelin-related genes in Schwann cells. This interaction is disrupted by neuropathy-associated mutations in EGR2, which specifically reduce SOX10 binding at the Mpz intron element, thereby affecting the expression of myelin genes such as Mpz, Mag, and Cx32 (LeBlanc2007NeuropathyAssociated).

The interaction between EGR2 and SOX10 is facilitated by the N-terminal region of EGR2, which is necessary for effective binding of SOX10 to the Mpz intron. Full-length EGR2 shows a stronger interaction with SOX10 compared to truncated versions lacking the N-terminal domain. Dominant-negative EGR2 mutants, such as EGR2 (SR/DY), inhibit this cooperative binding, leading to a loss of SOX10 binding at the Mpz intron (LeBlanc2007NeuropathyAssociated).

EGR2 expression is also regulated by NF-κB, a transcription factor that binds to the EGR2 promoter. This interaction suggests a regulatory mechanism where NF-κB activation triggers EGR2 expression, linking EGR2 to processes like synaptic plasticity and memory (Nafez2015Early).


## References


[1. (Sevilla2015The) T. Sevilla, R. Sivera, D. Martínez‐Rubio, V. Lupo, M. J. Chumillas, E. Calpena, J. Dopazo, J. J. Vílchez, F. Palau, and C. Espinós. The egr2 gene is involved in axonal charcot−marie−tooth disease. European Journal of Neurology, 22(12):1548–1555, July 2015. URL: http://dx.doi.org/10.1111/ene.12782, doi:10.1111/ene.12782. This article has 23 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1111/ene.12782)

[2. (Grosz2019A) Bianca R. Grosz, Natasha B. Golovchenko, Melina Ellis, Kishore Kumar, Garth A. Nicholson, Anthony Antonellis, and Marina L. Kennerson. A de novo egr2 variant, c.1232a &gt; g p.asp411gly, causes severe early-onset charcot-marie-tooth neuropathy type 3 (dejerine-sottas neuropathy). Scientific Reports, December 2019. URL: http://dx.doi.org/10.1038/s41598-019-55875-4, doi:10.1038/s41598-019-55875-4. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-019-55875-4)

[3. (ArthurFarraj2006A) Peter Arthur-Farraj, Rhona Mirsky, David B. Parkinson, and Kristjan R. Jessen. A double point mutation in the dna-binding region of egr2 switches its function from inhibition to induction of proliferation: a potential contribution to the development of congenital hypomyelinating neuropathy. Neurobiology of Disease, 24(1):159–169, October 2006. URL: http://dx.doi.org/10.1016/j.nbd.2006.06.006, doi:10.1016/j.nbd.2006.06.006. This article has 14 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.nbd.2006.06.006)

[4. (Warner1999Functional) L. E. Warner. Functional consequences of mutations in the early growth response 2 gene (egr2) correlate with severity of human myelinopathies. Human Molecular Genetics, 8(7):1245–1251, July 1999. URL: http://dx.doi.org/10.1093/hmg/8.7.1245, doi:10.1093/hmg/8.7.1245. This article has 110 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/8.7.1245)

[5. (Nafez2015Early) Solmaz Nafez, Kensuke Oikawa, Gary L. Odero, Michael Sproule, Ning Ge, Jason Schapansky, Bernard Abrenica, Avril Hatherell, Chris Cadonic, Shunzhen Zhang, Xiaohua Song, Tiina Kauppinen, Gordon W. Glazner, Mariagrazia Grilli, Michael P. Czubryt, David D. Eisenstat, and Benedict C. Albensi. Early growth response 2 (egr-2) expression is triggered by nf-κb activation. Molecular and Cellular Neuroscience, 64:95–103, January 2015. URL: http://dx.doi.org/10.1016/j.mcn.2014.12.008, doi:10.1016/j.mcn.2014.12.008. This article has 21 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.mcn.2014.12.008)

[6. (Benos2002Probabilistic) Panayiotis V. Benos, Alan S. Lapedes, and Gary D. Stormo. Probabilistic code for dna recognition by proteins of the egr family. Journal of Molecular Biology, 323(4):701–727, November 2002. URL: http://dx.doi.org/10.1016/S0022-2836(02)00917-8, doi:10.1016/s0022-2836(02)00917-8. This article has 150 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/S0022-2836(02)00917-8)

[7. (LeBlanc2007NeuropathyAssociated) Scott E. LeBlanc, Rebecca M. Ward, and John Svaren. Neuropathy-associated egr2 mutants disrupt cooperative activation of myelin protein zero by egr2 and sox10. Molecular and Cellular Biology, 27(9):3521–3529, May 2007. URL: http://dx.doi.org/10.1128/mcb.01689-06, doi:10.1128/mcb.01689-06. This article has 66 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.01689-06)

[8. (Funalot2012Homozygous) Benoît Funalot, Piotr Topilko, Maria Antonia Ramos Arroyo, Abdelaziz Sefiani, E. Tessa Hedley‐Whyte, Maria E. Yoldi, Laurence Richard, Estelle Touraille, Mathieu Laurichesse, Emmanuel Khalifa, Jasmine Chauzeix, Adama Ouedraogo, Didier Cros, Corinne Magdelaine, Franck G. Sturtz, J. Andoni Urtizberea, Patrick Charnay, Federico Garcia Bragado, and Jean‐Michel Vallat. Homozygous deletion of an egr2 enhancer in congenital amyelinating neuropathy. Annals of Neurology, 71(5):719–723, April 2012. URL: http://dx.doi.org/10.1002/ana.23527, doi:10.1002/ana.23527. This article has 16 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1002/ana.23527)

[9. (Okamura2012Roles) Tomohisa Okamura, Keishi Fujio, Shuji Sumitomo, and Kazuhiko Yamamoto. Roles of lag3 and egr2 in regulatory t cells. Annals of the Rheumatic Diseases, 71(Suppl 2):i96–i100, March 2012. URL: http://dx.doi.org/10.1136/annrheumdis-2011-200588, doi:10.1136/annrheumdis-2011-200588. This article has 58 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1136/annrheumdis-2011-200588)